Case number 2017-2088
Mylan Pharmaceuticals Inc. v. Research Corporation Tech. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | MYLAN PHARMACEUTICALS INC. v. RESEARCH CORPORATION TECH. [OPINION - PRECEDENTIAL] [precedential] (0) |
| Mar 11, 2019 | 93 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [591730] [17-2088, 17-2089, 17-2091] [JAB] [Entered: 03/11/2019 09:38 AM] (0) |
| Feb 1, 2019 | 91 | OPINION filed for the court by Lourie, Circuit Judge; Bryson, Circuit Judge and Wallach, Circuit Judge. Precedential Opinion. [582668] [17-2088, 17-2089, 17-2091] [PBC] [Entered: 02/01/2019 09:51 AM] (0) |
| Feb 1, 2019 | 92 | JUDGMENT filed. AFFIRMED. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. [582670] [17-2088, 17-2089, 17-2091] [PBC] [Entered: 02/01/2019 09:53 AM] (0) |
| Nov 7, 2018 | 90 | Submitted after ORAL ARGUMENT by Steven William Parmelee for Mylan Pharmaceuticals Inc., Breckenridge Pharmaceutical, Inc. and Alembic Phamaceuticals Ltd. and Jack B. Blumenfeld for Research Corporation Technologies, Inc.. Panel: Judge: Lourie , Judge: Bryson , Judge: Wallach. [563237] [JCP] [Entered: 11/07/2018 12:42 PM] (0) |
| Oct 16, 2018 | 88 | Notice to counsel for Appellants Alembic Pharmaceuticals Ltd. and Breckenridge Pharmaceutical, Inc.: The record of this case indicates that the Responses to the Oral Argument Order have not been filed. The responses were due on or before 10/15/2018. Counsel must promptly docket the Response to Oral Argument Order event and designate which attorneys will present argument for the parties. Service as of this date by the Clerk of Court. [557441] [JAB] [Entered: 10/16/2018 10:18 AM] (0) |
| Oct 16, 2018 | 89 | CORRECTED Response to oral argument order from the Appellants Mylan Pharmaceuticals Inc., Breckenridge Pharmaceutical, Inc. and Alembic Pharmaceuticals Ltd.. Designating Steven W. Parmelee to argue.. Designating 10 minutes for argument. Reserving 5 minutes for rebuttal. [17-2088] [Steven Parmelee] [Entered: 10/16/2018 12:57 PM] (0) |
| Oct 15, 2018 | 85 | Entry of appearance for Jack B. Blumenfeld as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 10/15/2018 by email. [557154] [17-2088] [Jack Blumenfeld] [Entered: 10/15/2018 03:08 PM] (0) |
| Oct 15, 2018 | 86 | Response to oral argument order from the Appellee Research Corporation Technologies, Inc.. Designating Jack B. Blumenfeld to argue.. Designating 15 minutes for argument. [17-2088] [Jack Blumenfeld] [Entered: 10/15/2018 03:10 PM] (0) |
| Oct 15, 2018 | 87 | Response to oral argument order from the Appellant Mylan Pharmaceuticals Inc.. Designating Steven W. Parmelee to argue.. Designating 10 minutes for argument. Reserving 5 minutes for rebuttal. [17-2088] [Steven Parmelee] [Entered: 10/15/2018 05:26 PM] (0) |
| Oct 12, 2018 | 84 | Entry of appearance for Nicole W. Stafford as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 10/12/2018 by email. [556752] [17-2088] [Steven Parmelee] [Entered: 10/12/2018 02:46 PM] (0) |
| Sep 21, 2018 | 83 | NOTICE OF CALENDARING. Panel: 1811I. Case scheduled Nov 07, 2018 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, NW Washington, DC 20439), Courtroom 203. Response to oral argument order due: 10/15/2018. Arguing counsel must check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [551774] [JAB] [Entered: 09/21/2018 03:16 PM] (0) |
| Sep 14, 2018 | 82 | Amended Entry of appearance for Alexa Hansen as principal counsel for Appellee Research Corporation Technologies, Inc.. Service: 09/14/2018 by email. [549787] [17-2088] [Alexa Hansen] [Entered: 09/14/2018 11:15 AM] (2) |
| Sep 14, 2018 | 81 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion to withdraw attorney Docket No. [77], ERROR: motion does not contain cert. of compliane with word count requirement. CORRECTION: future motions must contain this information. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [549782] [SJ] [Entered: 09/14/2018 11:05 AM] (0) |
| Sep 14, 2018 | 80 | **TEXT ONLY** ORDER granting motion to withdraw attorney [77] Andrea G. Reister filed by Appellee Research Corporation Technologies, Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [549780] [SJ] [Entered: 09/14/2018 11:03 AM] (0) |
| Sep 14, 2018 | 79 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: motion to withdraw attorney Docket No. [76], ERROR: motion does not appear to contain grounds or cert. of compliance with word count requirement. CORRECTION: future motions must contain this information. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [549778] [SJ] [Entered: 09/14/2018 11:00 AM] (0) |
| Sep 14, 2018 | 78 | **TEXT ONLY** ORDER granting motion to withdraw attorney [76] M. Jeffer Ali filed by Appellant Alembic Pharmaceuticals Ltd. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [549774] [SJ] [Entered: 09/14/2018 10:57 AM] (0) |
| Sep 13, 2018 | 77 | MOTION of Appellee Research Corporation Technologies, Inc. to withdraw counsel Andrea G. Reister [Consent: unopposed]. Service: 09/13/2018 by email. [549632] [17-2088] [Andrea Reister] [Entered: 09/13/2018 05:13 PM] (8) |
| Sep 13, 2018 | 76 | MOTION of Appellant Alembic Pharmaceuticals Ltd. to withdraw counsel M. Jeffer Ali [Consent: unopposed]. Service: 09/13/2018 by email. [549598] [17-2088] [Todd Werner] [Entered: 09/13/2018 03:59 PM] (6) |
| Sep 13, 2018 | 75 | Entry of appearance for Todd S. Werner as principal counsel for Appellant Alembic Pharmaceuticals Ltd.. Service: 09/13/2018 by email. [549597] [17-2088] [Todd Werner] [Entered: 09/13/2018 03:53 PM] (3) |
| Jul 30, 2018 | 74 | Notice from Appellee Research Corporation Technologies, Inc. regarding conflicts with oral argument (October 1-October 5, 2018; November 5-November 6, and November 8, 2018; December 3-December 7, 2018; January 7-January 11, 2019; February 4-February 8, 2019; and March 4-March 6, 2019.). Service: 07/30/2018 by email. [539438] [17-2088] [George Pappas] [Entered: 07/30/2018 03:11 PM] (2) |
| Apr 23, 2018 | 73 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellee Research Corporation Technologies, Inc.. Service: 04/23/2018 by email. [516116] [17-2088] [Andrea Reister] [Entered: 04/23/2018 02:53 PM] (4) |
| Mar 1, 2018 | 72 | Notice from Appellant Mylan Pharmaceuticals Inc. regarding conflicts with oral argument (April 2-9, 2018; April 30, 2018; May 1-4, 2018; June 4-8, 2018; September 4-5, 2018 ). Service: 03/01/2018 by email. [502215] [Steven Parmelee] [Entered: 03/01/2018 06:41 PM] (2) |
| Mar 1, 2018 | 71 | 6 paper copies of the Joint Appendix in 3 Volumes [67] received from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. [502135] [SJL] [Entered: 03/01/2018 03:35 PM] (0) |
| Mar 1, 2018 | 70 | Notice from Appellee Research Corporation Technologies, Inc. regarding conflicts with oral argument (Mar. 5-12, 2018; Apr. 2-9, 2018; Apr. 30-May 4, 2018; Aug. 6-10, 2018). Service: 03/01/2018 by email. [501956] [Alexa Hansen] [Entered: 03/01/2018 10:11 AM] (2) |
| Feb 27, 2018 | 69 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Appellee Research Corporation Technologies, Inc.. Service: 02/27/2018 by email. [501527] [Andrea Reister] [Entered: 02/27/2018 04:30 PM] (12) |
| Feb 23, 2018 | 68 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category.. [500830] [SJ] [Entered: 02/23/2018 04:27 PM] (0) |
| Feb 21, 2018 | 66 | 6 paper copies of the Reply Brief [63] received from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. [500137] [JCP] [Entered: 02/22/2018 08:00 AM] (0) |
| Feb 20, 2018 | 67 | APPENDIX FILED (3 vols.) for Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. [64]. Number of Pages: 1750. Service: 02/20/2018 by email. The paper copies of the brief should be received by the court on or before 03/02/2018. [500829] [SJ] [Entered: 02/23/2018 04:26 PM] (1750) |
| Feb 20, 2018 | 64 | TENDERED from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc., Mylan Pharmaceuticals Inc. and Appellee Research Corporation Technologies, Inc.. Title: JOINT APPENDIX. Service: 02/20/2018 by email. [499558] [Steven Parmelee] [Entered: 02/20/2018 09:27 PM] (1750) |
| Feb 20, 2018 | 65 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc., Mylan Pharmaceuticals Inc. and Appellee Research Corporation Technologies, Inc.. Service: 02/20/2018 by email. [499562] [Steven Parmelee] [Entered: 02/20/2018 09:31 PM] (12) |
| Feb 13, 2018 | 62 | TENDERED from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc.. Title: REPLY BRIEF. Service: 02/13/2018 by email. [497494] [Steven Parmelee] [Entered: 02/13/2018 07:40 PM] (46) |
| Feb 13, 2018 | 63 | REPLY BRIEF FILED for Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. [62]. Number of Pages: 32. Service: 02/13/2018 by email. The paper copies of the brief should be received by the court on or before 02/22/2018. Appendix is due 02/20/2018. [497530] [SJ] [Entered: 02/14/2018 09:09 AM] (46) |
| Jan 24, 2018 | 61 | 6 paper copies of the Opening Response Brief [58] received from Appellee Research Corporation Technologies, Inc. [492380] [CFT] [Entered: 01/24/2018 02:41 PM] (0) |
| Jan 19, 2018 | 60 | **TEXT ONLY** ORDER granting motion to extend time to file reply brief [59] filed by Appellants Breckenridge Pharmaceutical, Inc., Mylan Pharmaceuticals Inc. and Alembic Pharmaceuticals Ltd. Reply brief is due 02/13/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [491087] [SJ] [Entered: 01/19/2018 03:56 PM] (0) |
| Jan 19, 2018 | 59 | MOTION of Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. to extend the time to 02/13/2018 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 01/19/2018 by email. [491074] [Steven Parmelee] [Entered: 01/19/2018 03:43 PM] (11) |
| Jan 16, 2018 | 58 | BRIEF FILED for Appellee Research Corporation Technologies, Inc. [57]. Number of Pages: 65. Service: 01/16/2018 by email. The paper copies of the brief should be received by the court on or before 01/25/2018. Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. reply brief is due 01/30/2018. [490576] [SJ] [Entered: 01/18/2018 09:12 AM] (81) |
| Jan 16, 2018 | 57 | TENDERED from Appellee Research Corporation Technologies, Inc.. Title: RESPONSE BRIEF. Service: 01/16/2018 by email. [489974] [Alexa Hansen] [Entered: 01/16/2018 05:10 PM] (81) |
| Dec 1, 2017 | 56 | 6 paper copies of the Corrected Opening Brief [53] received from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. [479594] [CW] [Entered: 12/01/2017 12:06 PM] (0) |
| Nov 28, 2017 | 55 | **TEXT ONLY** ORDER granting motion to extend time to file appellee's principal brief [54] filed by Appellee Research Corporation Technologies, Inc. Appellee Research Corporation Technologies, Inc. brief due 01/16/2018. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [478646] [SJ] [Entered: 11/28/2017 02:36 PM] (0) |
| Nov 28, 2017 | 54 | MOTION of Appellee Research Corporation Technologies, Inc. to extend the time to 01/16/2018 to file the appellee/respondent/cross-appellant's principal brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 11/28/2017 by email. [478640] [Andrea Reister] [Entered: 11/28/2017 02:17 PM] (5) |
| Nov 21, 2017 | 53 | CORRECTED BRIEF FILED for Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. [52]. Number of Pages: 72. Service: 11/21/2017 by email. The paper copies of the brief should be received by the court on or before 12/01/2017. [477653] [SJ] [Entered: 11/22/2017 08:36 AM] (170) |
| Nov 21, 2017 | 52 | TENDERED from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc.. Title: CORRECTED OPENING BRIEF. Service: 11/21/2017 by email. [477632] [Steven Parmelee] [Entered: 11/21/2017 08:07 PM] (170) |
| Nov 21, 2017 | 51 | NOTICE OF REJECTION: The brief of Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc., Opening Brief [50], is not in compliance with the rules of this court and is therefore rejected for filing. Brief due 12/05/2017. Appellee Research Corporation Technologies, Inc. brief is due 01/02/2018. Service as of this date by Clerk of Court. [477349] [SJ] [Entered: 11/21/2017 11:27 AM] (2) |
| Nov 20, 2017 | 50 | TENDERED from Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc.. Title: OPENING BRIEF. Service: 11/20/2017 by email. [477221] This brief has been rejected. See Doc. No. [51] [Steven Parmelee] [Entered: 11/20/2017 11:14 PM] (0) |
| Oct 19, 2017 | 48 | ORDER filed. The motion [31] is denied. Service: 10/19/2017 by clerk. [469205] [LMS] [Entered: 10/19/2017 03:20 PM] (4) |
| Oct 19, 2017 | 49 | Clerk's Note to the File: Pursuant to FCR 31(c), appellants' opening brief(s) due Nov. 20, 2017. [469243] [SJ] [Entered: 10/19/2017 04:27 PM] (0) |
| Sep 12, 2017 | 43 | MOTION of Appellant Breckenridge Pharmaceutical, Inc. to withdraw counsel Rachel. Hughey and Jeffrey D. Blake. Any response is due within 10 days of service [Consent: opposed]. Service: 09/12/2017 by email. [460359] [Jeffrey Blake] [Entered: 09/12/2017 11:32 AM] (6) |
| Sep 12, 2017 | 47 | Entry of appearance for Aden M. Allen as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 09/12/2017 by email. [460546] [Aden Allen] [Entered: 09/12/2017 07:45 PM] (2) |
| Sep 12, 2017 | 44 | REPLY of Appellee Research Corporation Technologies, Inc. to response filed by Appellants in 17-2088 , Doc. No [35]. Service: 09/12/2017 by email. [460465] [Andrea Reister] [Entered: 09/12/2017 03:17 PM] (19) |
| Sep 12, 2017 | 45 | RESPONSE of Appellee Research Corporation Technologies, Inc. to the motion to withdraw attorney [43] filed by Appellant Breckenridge Pharmaceutical, Inc. in 17-2088. Service: 09/12/2017 by email. [460466] [Andrea Reister] [Entered: 09/12/2017 03:19 PM] (4) |
| Sep 12, 2017 | 46 | **TEXT ONLY** ORDER granting motion to withdraw attorneys J. Blake and R. Hughey [43] filed by Appellant Breckenridge Pharmaceutical, Inc.; withdrawing [41] motion to withdraw attorney filed by Appellant Breckenridge Pharmaceutical, Inc. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [460475] [SJ] [Entered: 09/12/2017 03:54 PM] (0) |
| Sep 11, 2017 | 40 | Amended Entry of appearance for Matthew L. Fedowitz as principal counsel for Appellant Breckenridge Pharmaceutical, Inc.. Service: 09/11/2017 by email. [460146] [Matthew Fedowitz] [Entered: 09/11/2017 02:26 PM] (2) |
| Sep 11, 2017 | 41 | MOTION of Appellant Breckenridge Pharmaceutical, Inc. to withdraw counsel Matthew L. Fedowitz. Any response is due within 10 days of service [Consent: unopposed]. Service: 09/11/2017 by email. [460147] [Jeffrey Blake] [Entered: 09/11/2017 02:28 PM] (6) |
| Sep 11, 2017 | 42 | Amended Entry of appearance for Rachel C. Hughey as principal counsel for Appellant Breckenridge Pharmaceutical, Inc.. Service: 09/11/2017 by email. [460150] [Rachel Hughey] [Entered: 09/11/2017 02:31 PM] (2) |
| Sep 7, 2017 | 39 | NOTICE OF DEFICIENCY: The attorney entry of appearance Document No. [37] filed by Appellant Breckenridge Pharmaceutical, Inc. in 17-2088 is indicating more than one principal attorney for the party(s) and therefore cannot be accepted for filing at this time [only govt. attorneys may use form to replace lead counsel]. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [459267] [SJ] [Entered: 09/07/2017 10:39 AM] (0) |
| Sep 6, 2017 | 38 | Entry of appearance for Jeffrey D. Blake as of counsel for Appellant Breckenridge Pharmaceutical, Inc.. Service: 09/06/2017 by email. [459127] [Rachel Hughey] [Entered: 09/06/2017 06:38 PM] (2) |
| Sep 6, 2017 | 37 | Entry of appearance for Rachel C. Hughey as principal counsel for Appellant Breckenridge Pharmaceutical, Inc.. Service: 09/06/2017 by email. [459126] [Rachel Hughey] [Entered: 09/06/2017 06:36 PM] (0) |
| Aug 29, 2017 | 36 | ORDER filed. The motion [34] is granted. Service: 08/29/2017 by clerk. [457404] [LMS] [Entered: 08/29/2017 02:19 PM] (2) |
| Aug 28, 2017 | 35 | RESPONSE of Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. to the motion to terminate appeal [31] filed by Appellee Research Corporation Technologies, Inc. in 17-2088. Service: 08/28/2017 by email. [457186] [Steven Parmelee] [Entered: 08/28/2017 09:44 PM] (1345) |
| Aug 24, 2017 | 34 | MOTION of Appellee Research Corporation Technologies, Inc. to extend time until 09/12/2017 to file (Reply to Appellants' Response to Motion to Dismiss). [Consent: unopposed]. Service: 08/24/2017 by email. [456392] [Andrea Reister] [Entered: 08/24/2017 01:43 PM] (5) |
| Aug 9, 2017 | 33 | ORDER filed. The motion [32] is granted. The Appellants' response to the Appellee's motion to dismiss is due on or before August 28, 2017. Service: 08/09/2017 by clerk. [452774] [LMS] [Entered: 08/09/2017 04:09 PM] (2) |
| Aug 7, 2017 | 32 | MOTION of Appellants Alembic Pharmaceuticals Ltd., Breckenridge Pharmaceutical, Inc. and Mylan Pharmaceuticals Inc. to extend the time to 08/28/2017 file a response/reply to the motion to terminate appeal [31]. [Consent: unopposed]. Service: 08/07/2017 by email. [451925] [Steven Parmelee] [Entered: 08/07/2017 09:02 PM] (6) |
| Aug 3, 2017 | 31 | MOTION of Appellee Research Corporation Technologies, Inc. to terminate appeal through dismissal. [Consent: opposed]. Service: 08/03/2017 by email. [451258] [Andrea Reister] [Entered: 08/03/2017 01:54 PM] (992) |
| Aug 3, 2017 | 30 | Entry of appearance for Evan S. Krygowski as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 08/03/2017 by email. [451254] [Evan Krygowski] [Entered: 08/03/2017 01:47 PM] (2) |
| Aug 3, 2017 | 29 | Entry of appearance for Jennifer L. Robbins as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 08/03/2017 by email. [451253] [Jennifer Robbins] [Entered: 08/03/2017 01:44 PM] (2) |
| Aug 3, 2017 | 28 | Entry of appearance for Beth S. Brinkmann as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 08/03/2017 by email. [451251] [Beth Brinkmann] [Entered: 08/03/2017 01:41 PM] (2) |
| Jul 5, 2017 | 27 | Certified list from the United States Patent and Trademark Office. Service: 07/05/2017 by email. Appellants' brief is due 09/05/2017. [444511] [17-2088] [SJ] [Entered: 07/06/2017 01:42 PM] (63) |
| Jun 9, 2017 | 25 | NOTICE OF DEFICIENCY: The certificate of interest Document No. [21] filed by Appellant Breckenridge Pharmaceutical, Inc. in 17-2088 is incomplete (question 4) and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [437773] [SJ] [Entered: 06/09/2017 10:07 AM] (0) |
| Jun 9, 2017 | 26 | Corrected Certificate of Interest for the Appellant Breckenridge Pharmaceutical, Inc.. Service: 06/09/2017 by email. [437913] [Matthew Fedowitz] [Entered: 06/09/2017 01:23 PM] (2) |
| Jun 8, 2017 | 20 | Entry of appearance for Jad A. Mills as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 06/08/2017 by email. [437699] [Steven Parmelee] [Entered: 06/08/2017 05:43 PM] (2) |
| Jun 8, 2017 | 24 | Docketing Statement for the Appellant Mylan Pharmaceuticals Inc.. Service: 06/08/2017 by email. [437703] [Steven Parmelee] [Entered: 06/08/2017 05:46 PM] (3) |
| Jun 8, 2017 | 23 | Docketing Statement for the Appellant Breckenridge Pharmaceutical, Inc.. Service: 06/08/2017 by email. [437702] [Matthew Fedowitz] [Entered: 06/08/2017 05:45 PM] (4) |
| Jun 8, 2017 | 22 | Certificate of Interest for the Appellant Mylan Pharmaceuticals Inc.. Service: 06/08/2017 by email. [437701] [Steven Parmelee] [Entered: 06/08/2017 05:44 PM] (3) |
| Jun 8, 2017 | 21 | Certificate of Interest for the Appellant Breckenridge Pharmaceutical, Inc.. Service: 06/08/2017 by email. [437700] [Matthew Fedowitz] [Entered: 06/08/2017 05:43 PM] (0) |
| Jun 8, 2017 | 19 | Entry of appearance for Michael T. Rosato as of counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 06/08/2017 by email. [437698] [Steven Parmelee] [Entered: 06/08/2017 05:42 PM] (2) |
| Jun 8, 2017 | 18 | Entry of appearance for Steven W. Parmelee as principal counsel for Appellant Mylan Pharmaceuticals Inc.. Service: 06/08/2017 by email. [437697] [Steven Parmelee] [Entered: 06/08/2017 05:41 PM] (2) |
| Jun 8, 2017 | 17 | Entry of appearance for MatthewL.Fedowitz as principal counsel for Appellant Breckenridge Pharmaceutical, Inc.. Service: 06/08/2017 by email. [437696] [Matthew Fedowitz] [Entered: 06/08/2017 05:40 PM] (2) |
| Jun 8, 2017 | 16 | Corrected Certificate of Interest for the Appellant Alembic Pharmaceuticals Ltd.. Service: 06/08/2017 by email. [437613] [M. Ali] [Entered: 06/08/2017 03:29 PM] (3) |
| Jun 8, 2017 | 15 | NOTICE OF DEFICIENCY: The certificate of interest Document No. [13] filed by Appellant Alembic Pharmaceuticals Ltd. in 17-2088 is incomplete (question 2) and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [437588] [SJ] [Entered: 06/08/2017 02:55 PM] (0) |
| Jun 8, 2017 | 14 | Docketing Statement for the Appellant Alembic Pharmaceuticals Ltd.. Service: 06/08/2017 by email. [437509] [M. Ali] [Entered: 06/08/2017 12:05 PM] (4) |
| Jun 8, 2017 | 13 | Certificate of Interest for the Appellant Alembic Pharmaceuticals Ltd.. Service: 06/08/2017 by email. [437501] [M. Ali] [Entered: 06/08/2017 12:01 PM] (0) |
| Jun 8, 2017 | 12 | Entry of appearance for Sarah M. Stensland as of counsel for Appellant Alembic Pharmaceuticals Ltd.. Service: 06/08/2017 by email. [437495] [M. Ali] [Entered: 06/08/2017 11:58 AM] (2) |
| Jun 8, 2017 | 11 | Entry of appearance for Jeffer Ali as principal counsel for Appellant Alembic Pharmaceuticals Ltd.. Service: 06/08/2017 by email. [437493] [M. Ali] [Entered: 06/08/2017 11:56 AM] (2) |
| Jun 8, 2017 | 10 | Corrected Certificate of Interest for the Appellee Research Corporation Technologies, Inc.. Service: 06/08/2017 by US mail, email. [437450] [Andrea Reister] [Entered: 06/08/2017 10:56 AM] (2) |
| Jun 8, 2017 | 9 | NOTICE OF DEFICIENCY: The certificate of interest Document No. [7] filed by Appellee Research Corporation Technologies, Inc. in 17-2088 is incomplete (question 3) and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [437387] [SJ] [Entered: 06/08/2017 09:03 AM] (0) |
| Jun 7, 2017 | 3 | Entry of appearance for Andrea G. Reister as principal counsel for Appellee Research Corporation Technologies, Inc.. Service: 06/07/2017 by US mail, email. [437129] [Andrea Reister] [Entered: 06/07/2017 01:42 PM] (2) |
| Jun 7, 2017 | 8 | Docketing Statement for the Appellee Research Corporation Technologies, Inc.. Service: 06/07/2017 by US mail, email. [437140] [Andrea Reister] [Entered: 06/07/2017 01:47 PM] (4) |
| Jun 7, 2017 | 7 | Certificate of Interest for the Appellee Research Corporation Technologies, Inc.. Service: 06/07/2017 by US mail, email. [437138] [Andrea Reister] [Entered: 06/07/2017 01:46 PM] (0) |
| Jun 7, 2017 | 6 | Entry of appearance for Priscilla G. Dodson as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 06/07/2017 by US mail, email. [437136] [Andrea Reister] [Entered: 06/07/2017 01:45 PM] (2) |
| Jun 7, 2017 | 5 | Entry of appearance for Alexa Hansen as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 06/07/2017 by US mail, email. [437133] [Andrea Reister] [Entered: 06/07/2017 01:44 PM] (2) |
| Jun 7, 2017 | 4 | Entry of appearance for George F. Pappas as of counsel for Appellee Research Corporation Technologies, Inc.. Service: 06/07/2017 by US mail, email. [437131] [Andrea Reister] [Entered: 06/07/2017 01:43 PM] (2) |
| May 25, 2017 | 1 | Appeal docketed. Received: 05/23/2017. [434213] Entry of Appearance due 06/08/2017. Certificate of Interest is due on 06/08/2017. Docketing Statement due 06/08/2017. Certified List due on 07/05/2017. [SJ] [Entered: 05/25/2017 03:53 PM] (63) |
| May 25, 2017 | 2 | Note to file: The following cases are associated:17-2088 (lead) with 17-2089 & 17-2091 (consolidated). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [434238] [17-2088, 17-2089, 17-2091] [SJ] [Entered: 05/25/2017 04:18 PM] (0) |
